Vical News
Most Popular Vical Story
NV1FGF - Top 10 Phase III Failures
The drug: NV1FGF The disease: Critical limb ischemia The companies: Sanofi-Aventis and Vical Sanofi-Aventis had high hopes for NV1FGF and the Tamaris Phase III study was designed to show that it was Read more...
Latest Headlines
- July 15, 2011
- October 21, 2010
- January 12, 2010
- May 27, 2009
- May 22, 2009
- February 13, 2009
- November 21, 2008
- July 17, 2008
- October 19, 2006
- July 25, 2006
- June 7, 2006
- May 29, 2006
- May 2, 2006
- March 26, 2006
- December 4, 2005
- June 13, 2005
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
